Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Almirall Prodesfarma patents new series of selective COX-2 inhibitors

May 11, 1999

M-5011 compares favorably to indomethacin in model of gouty arthritis

May 7, 1999

Novel naturally occurring proteasome inhibitor TMC-95A discovered at Tanabe Seiyaku

May 7, 1999

Potent and selective COX-2 inhibitors in the Glaxo Wellcome pipeline

May 4, 1999

Celebrex launched in Canada for arthritis

April 30, 1999

Positive results achieved in Alexion's phase I/II study of 5G1.1 in RA

April 27, 1999

Potent and selective COX-2 inhibitors described in recent patent literature by Novartis

April 23, 1999

Malonic acid-based MMP inhibitors with novel binding properties developed at Roche

April 23, 1999

Monsanto responds to press publication of Celebrex adverse events

April 22, 1999

Phytopharm reports preliminary phase IIa results for P-54 in osteoarthritis

April 22, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...